Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.
Valero IP, Pasquau J, Rubio R, Ribero A, Santos J, Sanz J, Mariño A, Crespo M, Hernandez J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Pérez-Molina JA. Valero IP, et al. Among authors: terron a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19656. doi: 10.7448/IAS.17.4.19656. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394160 Free PMC article.
Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.
López-Cortés LF, Viciana P, Ruiz-Valderas R, Pasquau J, Ruiz J, Lozano F, Merino D, Vergara A, Terrón A, González L, Rivero A, Muñoz-Sanz A. López-Cortés LF, et al. Among authors: terron a. AIDS Res Ther. 2010 Mar 17;7:5. doi: 10.1186/1742-6405-7-5. AIDS Res Ther. 2010. PMID: 20236544 Free PMC article.
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V; PERICO Study Group. Vispo E, et al. AIDS Res Hum Retroviruses. 2010 Apr;26(4):419-24. doi: 10.1089/aid.2009.0120. AIDS Res Hum Retroviruses. 2010. PMID: 20377423 Clinical Trial.
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group. Labarga P, et al. Among authors: terron a. J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807523 Clinical Trial.
Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
Pasquau J, López-Cortés L, Mayorga MI, Viciana P, Del Mar Arenas M, Ríos MJ, Hernández-Quero J, Castaño M, Merino MD, Márquez M, Vergara A, Terrón A, Téllez F, Hidalgo-Tenorio C. Pasquau J, et al. Among authors: terron a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19813. doi: 10.7448/IAS.17.4.19813. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397557 Free PMC article.
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group. Perez-Molina JA, et al. J Antimicrob Chemother. 2017 Jan;72(1):246-253. doi: 10.1093/jac/dkw379. Epub 2016 Sep 13. J Antimicrob Chemother. 2017. PMID: 27629070 Free article. Clinical Trial.
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Pérez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Crespo M, Hernández-Quero J, Iribarren JA, Gutiérrez F, Terrón A, Esteban H, Pérez-Molina JA; GESIDA 7011 Study Group members. Pérez-Valero I, et al. Among authors: terron a. J Antimicrob Chemother. 2018 Sep 1;73(9):2444-2451. doi: 10.1093/jac/dky212. J Antimicrob Chemother. 2018. PMID: 29897573 Free article. Clinical Trial.
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Hidalgo-Tenorio C, Pasquau J, Vinuesa D, Ferra S, Terrón A, SanJoaquín I, Payeras A, Martínez OJ, López-Ruz MÁ, Omar M, de la Torre-Lima J, López-Lirola A, Palomares J, Blanco JR, Montero M, García-Vallecillos C. Hidalgo-Tenorio C, et al. Among authors: terron a. Viruses. 2022 Mar 4;14(3):524. doi: 10.3390/v14030524. Viruses. 2022. PMID: 35336931 Free PMC article. Clinical Trial.
312 results